Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden

Table 3 Secondary outcomes: SF-36 change scores from baseline to end of study^a

RAND SF-36	Control group (n = 24)	MTM group (n = 25)	p value
Health domains
General health	–3.9 ± 14.9	4.3 ± 13.8	0.06
Physical functioning	3.6 ± 16.0	–5.2 ± 15.6	0.06
Bodily pain	1.8 ± 31.5	–6.8 ± 20.8	0.28
Role limitations, physical	4.6 ± 41.3	1.0 ± 32.5	0.75
Mental health	–6.1 ± 12.7	4.8 ± 12.5	0.005
Vitality	–4.9 ± 16.3	2.8 ± 12.9	0.08
Social functioning	–1.7 ± 29.2	0.5 ± 20.6	0.76
Role limitation, emotional	–6.1 ± 31.9	0.0 ± 32.6	0.53
Component scores
Physical health	1.5 ± 16.5	–1.2 ± 13.2	0.53
Mental health	–4.7 ± 14.0	2.1 ± 12.9	0.09

Data presented as mean ± SD or N (%)
MTM medication therapy management, SF-36 Short Form Health Survey
^aA negative result means a worsening on the measure between baseline and the end-of-study visit

ISSN: 1758-9193